Jay Caplan

People with #T1D deserve P3 clinical trials to study the cardioprotective and kidney-sparing actions of GLP-1 medicines nature.com/articles/s4159…

My essay in the Sunday Washington Post: “A viral infection can have devastating effects. I experienced this firsthand.” @AEIecon @PostOpinions wapo.st/3MhEY0U

FDA cannot verify the quality, safety, or efficacy of non-FDA approved drugs. fda.gov/news-events/pr…

@ohadhammer Love the slide. Thanks for sharing. Totally agree that patient convenience and tolerability will become key differentiators.

Next gen obesity pipeline in one slide from GS benchmarked against Wegovy and Zepbound. It still looks like adding new MOAs (amylin, glucagon) has an incremental effect and most new features will be related to patient convenience and tolerability. Bonus question: who can find a typo in the graph ? 🧐

@FractylHealth @washingtonpost @Harithr Full article available from Eric Topol at

GLP-1s changed metabolic care, but are not permanent solutions. A @WashingtonPost article, featuring our CEO and co-founder @HarithR, discusses how Fractyl Health is moving toward gene therapy for obesity and type 2 diabetes. Read more: washingtonpost.com/health/2026/01…

@GilesYeo @BBCRadio4 @BBCSounds Looking forward to the podcast here in the US

Coming soon 'The Hunger Game', a 5 part @BBCRadio4 programme that I have made about the rise and rise of obesity medications. Will transmit over the week of Feb 9, and then as a podcast on @BBCSounds bbc.co.uk/programmes/m00…

@doctorsaluja @cristinatejerap @DiabetesCareADA reviewofoptometry.com/article/glp1-g…

@cristinatejerap @DiabetesCareADA IS THE RISK OFFSET BY OTHER ADVANTAGES TO THE eye?

Association Between GLP-1 Receptor Agonists and Ischemic Optic Neuropathy: A Meta-analysis @DiabetesCareADA 🔗 diabetesjournals.org/care/article/d…

Joel Habener @MassGeneralNews @Harvard at one of the lab social gatherings in the mid 1980s with one of the labs talented research fellows, currently the President of @Penn Larry Jameson

Joel Habener pioneer in molecular biology, mentor, led foundational research that discovered a hormone dubbed GLP-1, which would later become the key ingredient in Ozempic and Mounjaro ⁦@MassGeneralNews⁩ ⁦@TheEndoSociety⁩ ⁦@Harvard⁩ wsj.com/health/pharma/…

📉 Our comprehensive review of Medication Adherence published in @DiabetologiaJnl Non-adherence affects ~38% of people T2 diabetes, Leads to higher HbA1c, more micro/macrovascular complications, hospitalisations, mortality, and major healthcare costs. 🔍 Causes span patient, socioeconomic, condition-related & system factors. 💊 Effective strategies: pharmacist-led care, fixed-dose combinations, and tailored, multifaceted interventions. Tech & motivational tools show mixed results. 🔑 Personalised, scalable solutions are urgently needed. #T2D #DiabetesCare #MedAdherence Led by Patrick Highton link.springer.com/article/10.100… With @mark_funnell @PankajLeicester @LeeLingLim1 @scelee1 @frazac

12 former commissioners of the FDA came together to write a Perspectives piece for the New England Journal of Medicine; raising our concerns about recent changes to vaccine approval policy at the FDA and its implications for patients and public health.

@BevTchangMD In the Surmount-4 trial, all patients received regular lifestyle counseling sessions delivered by a dietitian or qualified health care professional, focused on healthy, balanced meals with a 500-kcal/d deficit, and at least 150 min/wk of physical activity.

This slide from the SURMOUNT-4 trial shared by Dr. Dan Bessesen has my brain spinning. The waterfall plot on the left shows that about 4% of participants did NOT regain #weight after stopping tirzepatide I'd love to know the resting energy expenditure (REE), metabolic adaptation, and duration of #obesity in those 4% @EliLillyandCo Crucial knowledge to understanding what #weightloss maintenance can look like

Fantastic @DKThomp podcast with Drs. @seeleyrj and David Alessio (@DukeMedSchool) on #GLP1 - what they do, how, & current thinking on why they have such broad effects on metabolism & inflammation. podcasts.apple.com/us/podcast/if-…

@Maratosflier @DanielJDrucker @CellCellPress pubmed.ncbi.nlm.nih.gov/32422327/ put a damper on this approach

@DanielJDrucker @CellCellPress Are CCK agonists being developed?

The control of hunger in mice is regulated by DRN CCK neurons revealing a conserved cellular mechanism that transforms diverse neurohumoral signals into a key behavioral output @CellCellPress cell.com/cell/abstract/…

Honored to join the Board of Fractyl Health at such a pivotal moment. Revita® is advancing through late-stage development, and Rejuva® is preparing for first-in-human studies. Fractyl is redefining how we treat obesity and type 2 diabetes by addressing root causes, not just symptoms. Excited to help shape this next chapter.

Welcoming @MetabolicEndo and Ian Sheffield to our Board marks an important moment for Fractyl. Their expertise in pioneering new approaches to obesity care and in building healthcare businesses with lasting impact will help guide us through this next stage of growth. I’m also grateful to Amy Schulman for her service and leadership on our Board, and for helping position Fractyl to seize the opportunities ahead. Looking forward to the journey as we continue advancing Revita® and Rejuva® toward our goal of transforming metabolic care. $GUTS #FractylForward Revita® is for Investigational Use Only in the U.S. under Federal law. Rejuva® is in preclinical development and has not yet been assessed by regulatory agencies.

Happy special birthday to my friend and colleague the incomparable Jens Juul Holst @UCPH_Research @Metabolcenter @EASDnews @uni_copenhagen @novonordiskfond

For the rest of July, folks in the UK get 25% off when they preorder Food Intelligence (my book with @juliaoftoronto) at @Waterstones. waterstones.com/book/food-inte…

Distilling the complexity of nutrient sensing along the gut via the enteric nervous system nature.com/articles/s4158…

Encouraging my Canadian endocrine colleagues to read this and at least inform themselves. .